Last week, I gave a talk titled "The unchecked power of philanthropy" at an event called The Global Nicotine Forum in Warsaw. I explained how and why I'd decided to write about Bloomberg Philanthropies' campaign against electronic cigarettes, beginning with a long article in the Chronicle of Philanthropy in March of last year and continuing to this day.

The talk, delivered via Zoom, turned out to be timely. The campaign by Bloomberg and its allies surely contributed to the FDA's decision this week to ban products made by JUUL, a popular brand of e-cigarettes. That decision is misguided, in my view.

For reasons that I don't fully understand, the edited version of my talk, which I posted to Medium, has generated a lot of praise and become by far my best-read story ever on Medium. Here's a link.

Here we are, with summer coming to a close, and I am more than a little surprised to find that I have devoted most of my working time during 2021 to a single topic--electronic cigarettes. I’ve never been a smoker or a vaper, and paid no attention to e-cigarettes until late last year, when I began reporting a story about Bloomberg Philanthropies and the Campaign for Tobacco-Free Kids for the Chronicle of Philanthropy.

The more I learned, the more I came to believe that the topic meets the three criteria that I try to apply when deciding what stories to report. (1) Is it important? (2) Is it being covered well by others, i.e., do I have something to contribute? (3) Can my coverage in some way, big or small, make a difference?

(Those of you familiar with Effective Altruism will recognize those criteria as the framework of importance, neglectedness and tractability used by EA-influenced organizations such as the Open Philanthropy Project when deciding where to allocate resources to solve a problem.)

Yesterday, I posted a story with the headline “Vaping can benefit public health.” That’s not my opinion. It’s the conclusion of 15 former presidents of the Society for Research on Nicotine and Tobacco, who argue in a new paper that a growing body of evidence suggests that vaping, which is safer than smoking, can be an effective way of helping today’s smokers quit. “The potential lifesaving benefits of e-cigarettes for adult smokers deserve attention equal to the risks to youths,” these scientists write. “Millions of middle-aged and older smokers are at high risk of near-future disease and death.”

This is rebuke to, among others, government health authorities in the US and elsewhere, Bloomberg and Tobacco-Free Kids, all of which are pushing to restrict access to vapes. You can read my story here.

The philanthropy of the very rich is an exercise of power, says Stanford professor Rob Reich. As such, billionaire philanthropy deserves scrutiny and not automatic gratitude.

With that in mind, I began a deep dive three months ago into a campaign against electronic cigarettes funded largely by a $160-million, three-year grant from Bloomberg Philanthropies. Much of that went to the Campaign for Tobacco-Free Kids, the US's most powerful anti-tobacco nonprofit. Meantime, Michael Bloomberg, the patron of Bloomberg Philanthropies, billionaire founder of the Bloomberg media empire and former New York City mayor, spent millions of dollars of his own money fund political anti-vaping efforts, notably two ballot measures in San Francisco that led to ban on e-cigarettes in the city. A city where, not incidentally, you can still buy combustible cigarettes -- which are much more dangerous than e-cigs -- and marijuana. That makes no sense if what you care about is public health.

My research and reporting, which included 30 interviews, led to a story published today by The Chronicle of Philanthropy. The tobacco control movement is "neck-deep in intractable, internecine warfare" over vaping, Cliff Douglas, formerly of the American Cancer Society told me. Bloomberg, Tobacco-Free Kids and the major lung, cancer, and heart charities are on one side, opposing vaping, and pointing to its impact on kids and teens. Public health experts, by contrast, argue that e-cigarettes are a disruptive and potentially valuable technology that can and do help people quit smoking.

Little-known outside the world of psychedelics and drug policy, Rick Doblin is one of the most effective nonprofit leaders in America. Doblin is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies, better known as MAPS, which for 35 years has been trying to develop psychedelic medicines and advocating for the responsible use of psychedelic drugs.

Doblin, in my view, is a brilliant strategist who has done more to change the narrative around psychedelics than anyone, with the possible exception of the writer Michael Pollan. He has built political alliances on the right and left, worked closely with medical researchers and, as best as I can tell, made few enemies along the way. MAPS is on the verge of a major breakthrough by securing FDA approval for the use of MDMA, along with talk therapy, as a prescription medicine to treat PTSD.

I tell the remarkable story of Doblin and MAPS at some length in the new issue of the Stanford Social Innovation Review. The story is ordinarily paywalled but it is available for free until April 1. Here's a link.